MedTrace Logo

Identification of Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais , Normandy and Picardy Regions

NCT02121730 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2026-04-28

No results posted yet for this study

Summary

Kidney transplantation is now the treatment of choice for end-stage renal disease (ESRD). Between 2800 and 3000 kidney transplants are performed each year in France and more than 33 000 patients are living with a functioning graft.

Preventing allograft rejection requires the use of immunosuppressive therapy, the intensity decreases as the distance from the day of transplantation. Unfortunately, treatment favors certain complications, including infectious and neoplastic. These represent a major cause of mortality in these patients. If the frequency of skin cancer is greatly increased in this population, that of solid tumors remains a concern. Approximately 20% of patients develop cancer after 10 years of graft , half non- skin cancers, the main risk factor is immunosuppressive therapy .

The aim of the study is to evaluate, in a large population of patients treated in 4 regions ( the Nord-Pas de Calais, the Upper and Lower Normandy and Picardy) risk factors (in particular the nature of the immunosuppressive treatment) of developing a neoplastic complication, skin cancers and solid tumors, after renal transplantation.

Conditions

  • Cancer of Kidney

Sponsors & Collaborators

  • University Hospital, Caen

    collaborator OTHER

  • University Hospital, Lille

    collaborator OTHER

  • CHU ROUEN - HOPITAL DE BOIS-GUILLAUME

    collaborator UNKNOWN

  • Centre Hospitalier Universitaire, Amiens

    lead OTHER

Principal Investigators

  • Gabriel Choukroun, MD, PhD · CHU Amiens

  • Marc Hazzan, MD, PhD · CHRU LILLE

  • Bruno Hurault de Ligny, MD, PhD · University Hospital, Caen

  • Michel Godin, MD, PhD · CHU Rouen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-17
Primary Completion
2021-11-13
Completion
2022-08-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02121730 on ClinicalTrials.gov